The Stand Up 2 Cancer video supplied by biglabowski earlier this week is worthy of review, as the concept of the "mutational landscape" is sure to become the new lingo in ascertaining "best" biomarkers for any given patient. Imagine entering a treatment center from an initial PC diagnosis with your genome in your back pocket. Your personal chromosomal sequence, family history, select predictive & prognostic biomarkers, and your personal chemistry will create the guidelines for your personalized therapy. PSA is not necessarily to be considered the final assay. And...It's really not that far in the future... GLTA
Wilder.....I was at AACR this past 5 days and surely genomics is being pushed in more aggressively for certain types of cancer. SO you are absolutely correct that expression of certain markers is going to drive the patient therapy.